Publications by authors named "M F Pasetti"
Dysentery caused by Shigella species remains a major health threat to children in low- and middle-income countries. There is no vaccine available. The most advanced candidates, i.
View Article and Find Full Text PDFBackground: Following maternal COVID-19 vaccination, the persistence of antibodies in sera and breast milk for mothers and infants is not well characterized. We sought to describe the persistence of antibodies through 2 months after delivery in maternal and infant serum and breast milk following maternal COVID-19 mRNA vaccination and to examine differences by receipt of booster dose during pregnancy or postpartum.
Methods: This is a prospective cohort study with enrollment from July 2021 to January 2022 at 9 US academic sites.
Article Synopsis
- Pandemic influenza vaccine development emphasizes the importance of hemagglutinin (HA) and neuraminidase (NA) antibodies for effective immune responses.
- Clinical trials show that NA inhibition antibody responses increase with higher doses and extended intervals between vaccine doses, indicating a potential strategy for enhancing immunity.
- The study indicates that while neuraminidase responses can be improved for better pandemic preparedness, the antibody responses to the HA stalk were minimal and not long-lasting.
Training and temporally validating an NTCP model of acute toxicity after whole breast radiotherapy, including the impact of advanced delivery techniques.
Radiother Oncol
December 2024
Purpose: The aim is to train and validate a multivariable Normal Tissue Complication Probability (NTCP) model predicting acute skin reactions in patients with breast cancer receiving adjuvant Radiotherapy (RT).
Methods And Materials: We retrospectively reviewed 1570 single-institute patients with breast cancer treated with whole breast irradiation (40 Gy/15fr). The patients were divided into training (n = 878, treated with 3d-CRT, from 2009 to 2017) and validation cohorts (n = 692, treated from 2017 to 2021, including advanced RT techniques).
Article Synopsis
- Bacterial gastrointestinal diseases, particularly those caused by various Shigella species, lead to significant health issues globally, causing approximately 125 million cases of shigellosis and 14,000 deaths each year, mostly in young children in developing nations.
- A Phase 1 clinical trial evaluated the safety and tolerability of a new treatment called ShigActive™, a lytic bacteriophage aimed at Shigella, comparing its effects with a placebo over 29 days.
- Results showed that ShigActive™ was generally safe and well tolerated, with mild side effects reported by some participants and no serious adverse events, indicating it could be a potential option for treating shigellosis